| 查看: 699 | 回复: 6 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
sgh_119至尊木虫 (职业作家)
|
[交流]
【Pure water】First human trial of embryonic stem cells
|
||
|
US doctors have begun the first official trial of using human embryonic stem cells in patients after getting the green light from regulators. The Food and Drug Administration has given a license to Geron to use the controversial cells to treat people with spinal injuries. The cells have the potential to become many of the different cell types found in the body, including nerve cells. The trials at a hospital in Atlanta will check if the treatment is safe. Pivotal research Geron, a biotech company based in "silicon valley" south of San Francisco, has spent $170m on developing a stem cell treatment for spinal cord injury. The research will use cells coaxed to become nerve cells which are injected into the spinal cord. In animal trials of the treatment, paralysed rats regained some movement. But it is not yet known if it will offer any benefit to people with spinal cord injuries. Every year around 12,000 people in the US sustain spinal cord injuries. The most common causes are automobile accidents, falls, gunshot wounds and sports injuries. In the trial, patients who have sustained such an injury within the last 14 days will be given the experimental stem cell treatment. Geron president Dr Thomas Okarma said: "When we started working with human embryonic stem cells in 1999, many predicted that it would be a number of decades before a cell therapy would be approved for human clinical trials. "This accomplishment results from extensive research and development and a succession of inventive steps." But it will take some time to get the results. And there are many years of rigorous testing ahead before it can be known if the therapy is safe and effective. Professor Sir Ian Wilmut, director of the Medical Research Council Centre for Regenerative Medicine at the University of Edinburgh, said: "This is very exciting news, however, it is very important to appreciate that the objective of trials at this stage is to confirm first of all that no harm is done to patients, rather than to look for benefits. "Once that has been confirmed then the focus moves on to development and assessment of the new treatment." Ben Sykes, executive director of the UK National Stem Cell Network, said: "This is indeed a significant milestone in our journey towards the promise of stem cell-based medicines. "The global stem cell and regenerative medicine community will be awaiting the results of this safety trial with much anticipation." |
回复此楼» 猜你喜欢
271求调剂
已经有30人回复
-
材料类284调剂
已经有50人回复
-
291分调剂
已经有9人回复
-
调剂求收留
已经有34人回复
-
291 求调剂
已经有38人回复
-
22408 312求调剂
已经有17人回复
-
一志愿华中农业071010，320求调剂
已经有6人回复
-
290调剂生物0860
已经有41人回复
-
291求调剂
已经有3人回复
-
211本科材料化工求调剂
已经有23人回复
三更雨~
木虫 (文坛精英)
- ESEPI: 42
- 应助: 0 (幼儿园)
- 贵宾: 0.493
- 金币: 3701.9
- 散金: 4830
- 红花: 31
- 沙发: 69
- 帖子: 11421
- 在线: 1091.2小时
- 虫号: 863892
- 注册: 2009-10-06
- 性别: MM
- 专业: 光谱分析
5楼2010-10-12 08:56:29
xia_chong
金虫 (文坛精英)
- ESEPI: 43
- 应助: 0 (幼儿园)
- 贵宾: 1.591
- 金币: 10270.8
- 散金: 2377
- 红花: 34
- 沙发: 160
- 帖子: 12455
- 在线: 1941.8小时
- 虫号: 804303
- 注册: 2009-07-06
- 性别: GG
- 专业: 粒子物理学和场论
- 管辖: English Cafe
6楼2010-10-12 09:37:50
5